Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

ADVERTISEMENT

“Pan-coronavirus” vaccines: RNA Polymerase Emerges as a Vaccine Target

Resistance to COVID-19 infection has been observed in health care workers and has been attributed to the presence of memory T cells that target the RNA polymerase in the RTC (replication transcription complex), thereby preventing infection. This makes RNA polymerase an important target for making a pan-coronavirus vaccine that will be effective against SARS-CoV-2 and its other variants of concern (VoC’s), but also against the family of Coronaviruses in general. 

COVID-19 pandemic is now almost 2 years old and has caused havoc among the world by disrupting world economy and halting the normal way of living. Millions have died and many more have been infected with the disease leading to high levels of morbidity. However, there have been instances where people have cleared the infection from the system so quickly that they didn’t test positive for the virus or developed antibodies against it. This resistance has been attributed to the memory T cells-possibly those that are produced after exposure of the human system to such viruses

In a recent study published in Nature by Swalding et al., blood samples from 60 health care workers, who were at high risk of developing COVID-19 due to their exposure, were examined and found out to be negative for the virus and for the antibodies against the virus1. It is hypothesised that pre-existing memory T-cells, with cross-protective potential against SARS-CoV-2, expand in vivo to provide rapid viral clearance, thus aborting infection. These T cells are directed against the RNA polymerase in the RTC (replication transcription complex), rather than any other structural protein of the virus. These memory T cells could have been generated in the health care workers by being exposed to other respiratory or related corona viruses, albeit there is no direct evidence of the same. It is also possible that there were other environmental triggers that led to the generation of these T cells. In addition, these sero-negative individuals also showed an increase in IFI27, a protein indicative of abortive SARS-CoV-2 infection. IFI27 is an interferon alpha inducible protein that is overexpressed upon exposure to a variety of respiratory viruses, including SARS-CoV-2. This may also be responsible for viral clearance in individuals, pre-exposed to other respiratory viruses, and then infected with SARS-CoV-2. 

The fact that the memory T cells are directed against the RNA polymerase (being the most conserved among the human coronaviruses that cause common cold and SARS-CoV-2), makes this enzyme an important target to develop a pan-coronavirus vaccine that would not only be directed against SARS-CoV-2 and its other variants of concern (VoC’s) that have evolved as a result of mutations in the spike protein leading to more severe disease, but also against the family of Coronaviruses in general. 

*** 

Source:  

Swadling, L., Diniz, M.O., Schmidt, N.M. et al. Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. Nature (2021). https://doi.org/10.1038/s41586-021-04186-8 

***

Rajeev Soni
Rajeev Sonihttps://web.archive.org/web/20220523060124/https://www.rajeevsoni.org/publications/
Dr. Rajeev Soni (ORCID ID : 0000-0001-7126-5864) has a Ph.D. in Biotechnology from the University of Cambridge, UK and has 25 years of experience working across the globe in various institutes and multinationals such as The Scripps Research Institute, Novartis, Novozymes, Ranbaxy, Biocon, Biomerieux and as a principal investigator with US Naval Research Lab in drug discovery, molecular diagnostics, protein expression, biologic manufacturing and business development.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Most Popular Articles

Aviptadil Could Reduce Mortality Among Severely Ill COVID Patients

In June 2020, RECOVERY trial from a group of...

COVID-19 in England: Is Lifting of Plan B Measures Justified?

The government in England recently announced lifting of plan...

Vaccines for COVID-19: Race Against Time

Development of vaccine for COVID-19 is a global priority....
- Advertisement -
93,063FansLike
47,291FollowersFollow
1,772FollowersFollow
30SubscribersSubscribe